Nippon India Pharma Fund
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Growthvine rating: 4/5 — ranked #12 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹558.23 (as of 2026-10-01) |
|---|
| AUM | ₹9,479 Cr |
|---|
| Expense ratio | 1.51% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Sailesh Raj Bhan |
|---|
| Exit load | 1% for redemption within 30 days |
|---|
Performance & risk
| 5-year annualised return | 12.50% |
|---|
| Sharpe ratio | 0.86 |
|---|
| Standard deviation | 14.76% |
|---|
| Max drawdown | −47.36% |
|---|
| Alpha | -2.05 |
|---|
| Beta | 0.88 |
|---|
Over 5 years, captured 89.4% of NIFTY Pharma's upside and 87.1% of its downside.
Market cap allocation
| Large cap | 31.2% |
|---|
| Mid cap | 39.6% |
|---|
| Small cap | 29.1% |
|---|
Concentration
| Top 5 holdings | 37.0% |
|---|
| Top 10 holdings | 56.8% |
|---|
| Total holdings | 36 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 12.4%
- Divis Laboratories Ltd. — 7.0%
- Lupin Ltd — 6.4%
- Cipla Ltd. — 6.1%
- Apollo Hospitals Enterprises Ltd. — 5.2%
- Dr. Reddys Laboratories Ltd. — 4.9%
- Mankind Pharma Limited — 4.1%
- Sai Life Sciences Limited — 3.9%
- Ajanta Pharma Ltd. — 3.5%
- GlaxoSmithkline Pharmaceuticals Ltd. — 3.3%
Top sectors
- Pharma & Biotech — 74.0%
- Healthcare — 21.5%
- Retail — 2.5%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 9.6% | Q1 (Top) | #19 of 76 |
| 2025 | −3.3% | Q3 | #46 of 69 |
| 2024 | 34.0% | Q1 (Top) | #15 of 58 |
| 2023 | 39.2% | Q2 | #19 of 48 |
| 2022 | −9.9% | Q4 (Bottom) | #38 of 46 |